Nebraska Oncology Society 2020 Update on Advanced RCC: Is 1L Pembro+Axitinib More Beneficial for OS/PFS vs. Sunitiniby? What Is the ORR With Nivo+Ipi vs. Nivo Mono in Treatment-Naïve Patients?
By
Nebraska Oncology Society
FEATURING
Nicholas Vogelzang
By
Nebraska Oncology Society
FEATURING
Nicholas Vogelzang
Login to view comments.
Click here to Login